Anpac Bio CDA Liquid Biopsy Technology Selected by FAST COMPANY 2019 "WORLD CHANGING IDEAS AWARD"

SACRAMENTO,California,April 11,2019 --The editors and judges of Fast Company Magazine selected Anpac Bio-Medical Science Company's,"Cancer Differentiation Analysis" (CDA) Liquid Biopsy technology as an international,2019 Health & Wellness "World Changing Ideas Award" Honorable Mention recipient.

Fast Company Magazine selected Anpac Bio-Medical Science Company’s “Cancer Differentiation Analysis” (CDA) Liquid Biopsy technology as an international,2019 Health & Wellness “World Changing Ideas Award” Honorable Mention recipient this week. Anpac Bio’s CDA identifies 20+ cancers with a single,standard blood test – usually at the diseases’ earliest stages. Anpac Bio was selected by Fast Company judges tasked with recognizing,“…finished products and brave concepts that make the world better.”

Joining other "World Changing Ideas Award" (WCI) honorees such as: IBM,Intel,Amazon,NIKE,Boston Children's Hospital,Abbott,Microsoft,National Geographic,Gilead,Fitbit,Google,Siemens,Thermo Fisher Scientific,and The Bill & Melinda Gates Medical Research Institute,among others,Anpac Bio was recognized by Fast Company judges tasked with identifying,"...finished products and brave concepts that make the world better."

WCI award recipients were selected from among over 2,000 nominations worldwide,based on feasibility and the potential for impact; and with a goal of awarding,"ingenuity and fostering innovation."

Previously described as "game changing",and receiving the,"Breakthrough Innovation Award",at the World Nobel Prize Laureate Summit; and named,"Most Promising Cancer Screening Company",at the Global Precision Medicine Industry Awards;Anpac Bio was also recently selected by the United States Department of Commerce as the,"Minority Health Firm of the Year",due to the company's remarkable,CDA liquid biopsy technology.

Anpac Bio pioneered liquid biopsy cancer screening research. Comprehensive research validity data from 140,000+ cases (to date),and independently-corroborated by world-renowned hospitals and cancer research leaders,demonstrate CDA diagnostics consistently detects over 20 types of cancer,with 80%-90% sensitivity and specificity rates -- usually at the diseases' earliest stages. And it does so without any harmful patient side effects; generatingfar fewer "false positives"; at a cost substantially lower than traditional testing (such as imaging); and generating results within minutes of sample submission. Anpac Bio has filed over 200 CDA-related patent applications worldwide- 110 issued in 20 countries and regions (to date).

"Our Anpac Bio team is very proud to receive the 'World Changing Ideas' recognition from Fast Company," states Dr. Chris Yu,Anpac Bio CEO. "We believe the most important,world changing health ideas must be related to the early detection and prevention of disease. Our CDA technology was developed to achieve those goals. And we are now saving an average of two patients every week by catching their cancer at the earliest stages. We thank Fast Company for this great honor."

For further information: AnpacBio.com.

Fast Company Magazine judges selected Anpac Bio-Medical Science Company’s,“Cancer Differentiation Analysis” (CDA) Liquid Biopsy technology as an international,2019 Health & Wellness “World Changing Ideas Award” (WCI) Honorable Mention recipient. Anpac Bio’s CDA identifies 20+ early-stage cancers with a single blood test. WCI award recipients were selected from over 2,based on the Ideas’ feasibility; potential for impact; and demonstrated ingenuity and innovation.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough,proprietary,"Cancer Differentiation Analysis" liquid biopsy technology that effectively reinvents cancer screening and early detection. Anpac Bio's proprietary CDA medical devices analyze simple,standard,non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity,with no harmful side effects in patients. The proven results of 120,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for 28+ different types of cancer -- often identifying the type and location of threatening,diseased cancer cells before they form into tumors. Fully-commercialized and the only company earning liquid biopsy revenue globally,Anpac Bio has filed 250+ CDA-related Patents; 101+ issued to date worldwide. For more information: AnpacBio.com.

Photo - http://cusmail.com/res/2023/07-22/18/e0a4ec412cb304c3a8f448a55dde029d.jpg

Photo - http://cusmail.com/res/2023/07-22/18/b7a4d93c100a239bcbc3aedeae003542.jpg

Logo - http://cusmail.com/res/2023/07-22/18/6547562bb6a417e87b31ccaad6becebc.jpg